November 3, 2017 News by Janet Stewart, MSc RedHill Awaits US Patent for Antibiotic Combo, RHB-104, as Potential RRMS Therapy RedHill Biopharma has received aĀ Notice of AllowanceĀ for a new patent onĀ RHB-104Ā its potential therapy for patients with relapsing-remitting multiple sclerosis (RRMS). Once granted by the United States Patent and Trademark Office (USPTO),Ā this patent will be valid until 2032. RHB-104 is a proprietary, orally-administered antibiotic combinationĀ with potentially potent intracellular, antimycobacterial…
December 14, 2016 News by Patricia Silva, PhD Trial Data Suggests RedHill’s Antibiotic Treatment May Benefit MS Patients Promising data from a small Phase 2a clinical trial sponsored byĀ RedHill BiopharmaĀ for an antibiotic designed to fight certain infections suggests thatĀ adding the drug candidate to interferon treatment reduced relapse rates and brain lesion formation in patients with relapsing forms of multiple sclerosis (MS). This novelĀ treatment approach was based on…
October 20, 2016 News by Patricia Silva, PhD RedHill Awaits Patent for RHB-104, Potential MS Treatment, from Japan RedHill BiopharmaĀ recentlyĀ announcedĀ that it hasĀ received a Notice of Allowance from theĀ Japan Patent Office for a new patent coveringĀ RHB-104 as a potentialĀ treatment of multiple sclerosis (MS).Ā Once granted, the patent will be valid until 2032. The European Patent Office also recently approvedĀ a patent application for the drug with this…
August 30, 2016 News by Joana Fernandes, PhD Potential Relapsing MS Therapy, RHB-104, to Get New European Patent The European Patent Office has releasedĀ a Notice of Intention to Grant a new patent to support RHB-104 as a therapyĀ for relapsing-remitting multiple sclerosis (RRMS). RHB-104 is being developed Ā byĀ RedHill Biopharma. Patents covering the use of RHB-104 exist in over 25 countries, including the U.S., Australia, Canada, Japan, and in…
August 3, 2016 News by admin Phase 2 Study of Oral Antibiotic to Treat Relapsing MS, RHB-104, Nearing Finish RedHill Biopharma announced that theĀ final patient has completed the last step of itsĀ Phase 2 clinical study (CEASE-MS) of RHB-104 as a potential treatment forĀ people with relapsing-remitting multiple sclerosis (RRMS). RHB-104 is an antibiotic oral medication that blocks inflammation in addition to killing bacteria. RHB-104 was originally developedĀ as a treatment for…
April 4, 2016 News by Margarida Azevedo, MSc Experimental MS Oral Antibiotic Combination Therapy Showing Promise in Phase 2a Study, RedHill Biopharma Reports RedHill Biopharma, Ltd.Ā recently announced promising interim results from itsĀ ongoing CEASE-MS Phase 2a clinical trial evaluating the safety and efficacy of a fixed dose of RHB-104 as an add-onĀ therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). RHB-104 consists of an oral capsule formulation of an antibiotic combination therapy ā…
February 12, 2016 News by Margarida Azevedo, MSc RedHill’s Experimental MS Therapy, RHB-104, Receives Notice of Allowance on U.S. Patent RedHill Biopharma, Ltd., an Israeli biopharmaceutical company focused on the development and commercialization of oral-administered small-molecule medicines for the treatment of inflammatory and gastrointestinal diseases, recently announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent covering its…
December 3, 2015 News by Patricia Silva, PhD RRMS Clinical Study of New Antibiotic Therapy Nearing End RedHill Biopharma, Ltd., recently announced the conclusion of the last dosing and patient follow-up visit for its Phase 2a proof-of-concept study to assess the efficacy and safety of the experimental drug RHB-104 as an add-on therapy to interferon beta-1a in patients with relapsing-remitting multiple sclerosis (RRMS).
June 10, 2015 News by Maureen Newman RedHill Biopharma Enrolls Final RRMS Patient in RHB-104 Clinical Trial RedHill Biopharma Ltd. enrolled the final patient for its Phase IIa, proof-of-concept study testing RHB-104 in patients with relapsing remitting multiple sclerosis (RRMS) who test positive for Mycobacterium avium subsp. paratuberculosis (MAP). RedHill is evaluating RHB-104 as an add-on therapy to interferon beta-1a for a treatment…